The experienced team of scientists at FlowMetric Diagnostics, a division of FlowMetric Life Sciences Inc. (FlowMetric), developed VaxEffect to be the
world’s first COVID-19 vaccine immune response test built upon superior Flow Cytometry technology.
FlowMetric is a globally recognized life sciences company with over a decade of experience combining its deep expertise in immunology with multiparameter high-throughput Flow Cytometry, supporting many of the world’s best and largest healthcare companies in their drug development and vaccine initiatives.
At VaxEffect, we are passionate in providing powerful information to help physicians empower a patient’s well-being.
The VaxEffect Test has been created to assess the effectiveness of all vaccines, beginning with the COVID-19 vaccine.
The VaxEffect COVID-19 Vaccine Immune Response Test is the…
First and only patent pending quantitative COVID-19 serology test built upon a flow cytometry platform.
Created exclusively to assess and track an individual’s immune response to COVID-19 vaccination or prior exposure to the virus.
Compared to other serology platforms, such as ELISA and lateral flow, VaxEffect uses a flow cytometry technology platform.
Provides significantly more information and delivers high clinical sensitivity and specificity as well as a wider range of detection than traditional tests.
The VaxEffect test has been developed, validated and is analyzed in a CLIA Certiﬁed and CAP accredited, High Complexity Laboratory.